AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Atlantis Symbicort
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)Drug: fluticasone/salmeterol (Advair)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00646594
Long-term Safety in Atrial Fibrillation Patients
Phase 2
Completed
- Conditions
- Persistent or Permanent Nonvalvular Atrial Fibrillation
- Interventions
- Drug: AZD0837Drug: VKA INR 2-3
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 523
- Registration Number
- NCT00645853
Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)Drug: budesonide
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00646321
Symbicort Onset of Action 2
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00646009
Gemini Symbicort pMDI
Phase 3
Completed
- Conditions
- Mild or Moderate Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 615
- Registration Number
- NCT00646516
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00644735
Quality Of Life While Receiving Faslodex
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00643513
- Locations
- 🇷🇺
Research Site, Yakutsk, Russian Federation
Explorative Study of AZD1305 in Atrial Fibrillation Patients
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: AZD1305Drug: Placebo
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00643448
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 994
- Registration Number
- NCT00643851
- Locations
- 🇺🇸
Southeastern Research Associates, Inc., Greenville, South Carolina, United States
🇺🇸Jackson Clinic, Rolling Fork, Mississippi, United States
🇺🇸Community Health Care, Inc., Canal Fulton, Ohio, United States
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Phase 2
Completed
- Conditions
- Stable Coronary Artery Disease
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00642811
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath